SwePub
Sök i LIBRIS databas

  Utökad sökning

onr:"swepub:oai:gup.ub.gu.se/302013"
 

Sökning: onr:"swepub:oai:gup.ub.gu.se/302013" > Pathophysiological ...

LIBRIS Formathandbok  (Information om MARC21)
FältnamnIndikatorerMetadata
00005778naa a2200697 4500
001oai:gup.ub.gu.se/302013
003SwePub
008240528s2020 | |||||||||||000 ||eng|
009oai:prod.swepub.kib.ki.se:145851712
024a https://gup.ub.gu.se/publication/3020132 URI
024a https://doi.org/10.1093/brain/awaa3252 DOI
024a http://kipublications.ki.se/Default.aspx?queryparsed=id:1458517122 URI
040 a (SwePub)gud (SwePub)ki
041 a eng
042 9 SwePub
072 7a ref2 swepub-contenttype
072 7a art2 swepub-publicationtype
100a Tijms, B. M.4 aut
2451 0a Pathophysiological subtypes of Alzheimer's disease based on cerebrospinal fluid proteomics
264 c 2020-11-18
264 1b Oxford University Press (OUP),c 2020
520 a Alzheimer's disease is biologically heterogeneous, and detailed understanding of the processes involved in patients is critical for development of treatments. CSF contains hundreds of proteins, with concentrations reflecting ongoing (patho)physiological processes. This provides the opportunity to study many biological processes at the same time in patients. We studied whether Alzheimer's disease biological subtypes can be detected in CSF proteomics using the dual clustering technique non-negative matrix factorization. In two independent cohorts (EMIF-AD MBD and ADNI) we found that 705 (77% of 911 tested) proteins differed between Alzheimer's disease (defined as having abnormal amyloid, n=425) and controls (defined as having normal CSF amyloid and tau and normal cognition, n=127). Using these proteins for data-driven clustering, we identified three robust pathophysiological Alzheimer's disease subtypes within each cohort showing (i) hyperplasticity and increased BACE1 levels; (ii) innate immune activation; and (iii) blood-brain barrier dysfunction with low BACE1 levels. In both cohorts, the majority of individuals were labelled as having subtype 1 (80, 36% in EMIF-AD MBD; 117, 59% in ADNI), 71 (32%) in EMIF-AD MBD and 41 (21%) in ADNI were labelled as subtype 2, and 72 (32%) in EMIF-AD MBD and 39 (20%) individuals in ADNI were labelled as subtype 3. Genetic analyses showed that all subtypes had an excess of genetic risk for Alzheimer's disease (all P>0.01). Additional pathological comparisons that were available for a subset in ADNI suggested that subtypes showed similar severity of Alzheimer's disease pathology, and did not differ in the frequencies of co-pathologies, providing further support that found subtypes truly reflect Alzheimer's disease heterogeneity. Compared to controls, all non-demented Alzheimer's disease individuals had increased risk of showing clinical progression (all P<0.01). Compared to subtype 1, subtype 2 showed faster clinical progression after correcting for age, sex, level of education and tau levels (hazard ratio = 2.5; 95% confidence interval = 1.2, 5.1; P=0.01), and subtype 3 at trend level (hazard ratio = 2.1; 95% confidence interval = 1.0, 4.4; P=0.06). Together, these results demonstrate the value of CSF proteomics in studying the biological heterogeneity in Alzheimer's disease patients, and suggest that subtypes may require tailored therapy.
650 7a MEDICIN OCH HÄLSOVETENSKAPx Medicinska och farmaceutiska grundvetenskaperx Neurovetenskaper0 (SwePub)301052 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Basic Medicinex Neurosciences0 (SwePub)301052 hsv//eng
653 a Alzheimer's disease
653 a cerebrospinal fluid
653 a proteomics
653 a subtypes
653 a Neurosciences & Neurology
700a Gobom, Johanu Gothenburg University,Göteborgs universitet,Institutionen för neurovetenskap och fysiologi, sektionen för psykiatri och neurokemi,Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry4 aut0 (Swepub:gu)xgobjo
700a Reus, L.4 aut
700a Jansen, I.4 aut
700a Hong, S. J.4 aut
700a Dobricic, V.4 aut
700a Kilpert, F.4 aut
700a ten Kate, M.4 aut
700a Barkhof, F.4 aut
700a Tsolaki, M.4 aut
700a Verhey, F. R. J.4 aut
700a Popp, J.u Karolinska Institutet4 aut
700a Martinez-Lage, P.4 aut
700a Vandenberghe, R.4 aut
700a Lle, A.4 aut
700a Molinuevo, J. L.4 aut
700a Engelborghs, S.4 aut
700a Bertram, L.4 aut
700a Lovestone, S.4 aut
700a Streffer, J.4 aut
700a Vos, S.4 aut
700a Bos, I.4 aut
700a Blennow, Kaj,d 1958u Gothenburg University,Göteborgs universitet,Institutionen för neurovetenskap och fysiologi, sektionen för psykiatri och neurokemi,Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry4 aut0 (Swepub:gu)xbleka
700a Scheltens, P.4 aut
700a Teunissen, C. E.4 aut
700a Zetterberg, Henrik,d 1973u Gothenburg University,Göteborgs universitet,Institutionen för neurovetenskap och fysiologi, sektionen för psykiatri och neurokemi,Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry4 aut0 (Swepub:gu)xzethe
700a Visser, P. J.4 aut
710a Göteborgs universitetb Institutionen för neurovetenskap och fysiologi, sektionen för psykiatri och neurokemi4 org
773t Braind : Oxford University Press (OUP)g 143, s. 3776-3792q 143<3776-3792x 0006-8950x 1460-2156
856u https://academic.oup.com/brain/article-pdf/143/12/3776/36123503/awaa325.pdf
8564 8u https://gup.ub.gu.se/publication/302013
8564 8u https://doi.org/10.1093/brain/awaa325
8564 8u http://kipublications.ki.se/Default.aspx?queryparsed=id:145851712

Hitta via bibliotek

  • Brain (Sök värdpublikationen i LIBRIS)

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy